Incyclix Bio is a clinical stage pharmaceutical company developing small molecule inhibitors of cyclin-dependent kinases (CDKs) for the treatment of advanced and resistant cancers. The team’s unique insights about the biology and structure of CDKs will facilitate the rapid discovery and development of a novel, potent, and selective CDK2 inhibitor to treat patients whose tumors are insensitive to CDK4/6 inhibition.
Transforming the future of arrhythmia therapeutics.
Working with governments, international agencies, and private sector partners, Med Aditus seeks to revolutionize access to medicine in Sub-Saharan Africa, from product development and manufacturing to secure supply chains and patient delivery to provide healthier and longer life though better access to medicines.